Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2− advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): Efficacy, safety, and biomarker results
Bardia, Aditya, Hurvitz, Sara A., DeMichele, Angela, Clark, Amy Sanders, Zelnak, Amelia Bruce, Yardley, Denise A., Karuturi, Meghan Sri, Sanft, Tara B., Blau, Sibel, Hart, Lowell L., Ma, Cynthia X., Caria, Nicola, Purkayastha, D. Das, Mistry, Alomi, Moulder, Stacy L.
Published in Journal of clinical oncology (20.05.2019)
Published in Journal of clinical oncology (20.05.2019)
Get full text
Journal Article